A number of Canadian companies now stand at the forefront of medical cannabis – a massive global growth industry – leveraging the demand for cannabis and cannabinoid products at home and increasingly establishing positions as global leaders. Through the exclusive insights of the Canadian medical cannabis industry’s leading executives, this report explores how companies are navigating the regulatory environment is what is still a young sector; which organizations are taking their cues from the more mature biotech industry to develop clinical trials or partner with pharma companies; how massive funding injections are being secured via public listings; and how Canadian companies are leveraging their homegrown expertise to take their products and services to medical cannabis hotspots around the globe.